Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.90)
# 1,458
Out of 4,820 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $14.40 | +52.78% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.29 | +32.92% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $4.90 | +63.27% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $15.22 | +228.52% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $107.21 | +26.85% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $3.77 | +324.40% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $9.69 | +539.83% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.13 | +961.95% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $7.60 | +176.32% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $60.85 | +79.13% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.05 | +661.90% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $1.41 | +609.22% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.32 | +1,462.50% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $4.17 | +43.88% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $2.72 | +672.06% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $71.40 | -67.79% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $21.03 | +71.18% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $14.40
Upside: +52.78%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.29
Upside: +32.92%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $4.90
Upside: +63.27%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $15.22
Upside: +228.52%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $107.21
Upside: +26.85%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $3.77
Upside: +324.40%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $9.69
Upside: +539.83%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.13
Upside: +961.95%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $7.60
Upside: +176.32%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $60.85
Upside: +79.13%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.05
Upside: +661.90%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $1.41
Upside: +609.22%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.32
Upside: +1,462.50%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $4.17
Upside: +43.88%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $2.72
Upside: +672.06%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $71.40
Upside: -67.79%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $21.03
Upside: +71.18%